Almac to Partner with Lilly UK on Lung Cancer Dx

Almac and Lilly will study a predictive marker for use as a companion diagnostic for a combination therapy.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories